Please Wait
Applying Filters...
menu
    • menu
    Gentec Pharmaceutical Group is focused on manufacturing & developing APIs/HPAPIs, Advanced Intermediates & Fine Chemicals.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Evonik

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Temad- We think of world-class quality.

    Virtual Booth

    Contact Supplier

    Menu

    AL001

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 68Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Alzamend starts Phase II trial of AL001 at Massachusetts Hospital
    Alzamend starts Phase II trial of AL001 at Massachusetts Hospital

    18 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2025/03/18/3044409/0/en/Alzamend-Neuro-Announces-Initiation-Date-of-Phase-II-Clinical-Trial-of-AL001-for-Treatment-of-Major-Depressive-Disorder-to-take-Place-at-Massachusetts-General-Hospital.html

    GLOBENEWSWIRE
    18 Mar 2025
    Share Share
    Alzamend Neuro Announces Initiation of PI First-in-Human Clinical Trial of AL001
    Alzamend Neuro Announces Initiation of PI First-in-Human Clinical Trial of AL001

    13 Sep 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210913005330/en

    BUSINESSWIRE
    13 Sep 2021
    Share Share
    Alzamend Neuro and Altasciences to conduct a Phase I study for AL001.
    Alzamend Neuro and Altasciences to conduct a Phase I study for AL001.

    17 Aug 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210817005396/en

    BUSINESSWIRE
    17 Aug 2021
    Share Share